South Dakota Investment Council Grows Position in IQVIA Holdings Inc. $IQV

South Dakota Investment Council boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,712 shares of the medical research company’s stock after buying an additional 23,813 shares during the period. South Dakota Investment Council owned 0.05% of IQVIA worth $13,823,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IQV. Brighton Jones LLC boosted its stake in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Mather Group LLC. boosted its stake in shares of IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after buying an additional 350 shares during the period. Private Trust Co. NA grew its holdings in shares of IQVIA by 22.4% during the first quarter. Private Trust Co. NA now owns 536 shares of the medical research company’s stock worth $94,000 after buying an additional 98 shares during the last quarter. Teacher Retirement System of Texas increased its position in IQVIA by 201.6% in the 1st quarter. Teacher Retirement System of Texas now owns 32,432 shares of the medical research company’s stock valued at $5,718,000 after acquiring an additional 21,679 shares during the period. Finally, Mutual Advisors LLC raised its stake in IQVIA by 85.1% during the 1st quarter. Mutual Advisors LLC now owns 3,126 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 1,437 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $216.43 on Monday. The firm’s fifty day simple moving average is $197.12 and its 200-day simple moving average is $174.12. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $36.86 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 2.42 and a beta of 1.34. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $225.91.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the business earned $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. UBS Group lifted their target price on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on shares of IQVIA in a report on Wednesday, September 3rd. Finally, Barclays boosted their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $241.41.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.